SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 104 000 KRW -0.1% Market Closed
Market Cap: 8.1T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SK Biopharmaceuticals Co Ltd
Interest Income Expense Peer Comparison

Comparables:
000100
008930
128940
S
000250
C
068760

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Interest Income Expense
-â‚©11.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Interest Income Expense
â‚©65.9B
CAGR 3-Years
-3%
CAGR 5-Years
6%
CAGR 10-Years
0%
Hanmi Science Co Ltd
KRX:008930
Interest Income Expense
â‚©70.8B
CAGR 3-Years
93%
CAGR 5-Years
36%
CAGR 10-Years
35%
Hanmi Pharm Co Ltd
KRX:128940
Interest Income Expense
-â‚©15.4B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
-2%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Interest Income Expense
-â‚©4.9B
CAGR 3-Years
N/A
CAGR 5-Years
-39%
CAGR 10-Years
N/A
C
Celltrion Pharm Inc
KOSDAQ:068760
Interest Income Expense
-â‚©7B
CAGR 3-Years
-24%
CAGR 5-Years
-6%
CAGR 10-Years
-13%

See Also

What is SK Biopharmaceuticals Co Ltd's Interest Income Expense?
Interest Income Expense
-11.5B KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Interest Income Expense amounts to -11.5B KRW.

What is SK Biopharmaceuticals Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
26%

Over the last year, the Interest Income Expense growth was 26%.

Back to Top